ChemicalBook > Product Catalog >Biochemical Engineering >Antibody >Abrilumab

Abrilumab

Request For Quotation
Abrilumab Suppliers list
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
Company Name: ShangHai Biochempartner Co.,Ltd  
Tel: 177-54423994 17754423994
Email: 2853530910@QQ.com
Company Name: BOC Sciences  
Tel: 16314854226; +8616314854226
Email: inquiry@bocsci.com
Company Name: TargetMol Chemicals Inc.  
Tel: +1-781-999-5354; +1-00000000000
Email: marketing@targetmol.com
Company Name: Guangzhou Hongyuan Chemical Co.,Ltd  
Tel: 15817493340
Email: 981810490@qq.com

Abrilumab manufacturers

  • Abrilumab
  • Abrilumab pictures
  • $148.00
  • 2026-08-08
  • CAS:1342290-43-0
  • Purity: 98.5% (SDS-PAGE); 99% (SEC-HPLC)
  • Supply Ability: 10g
Abrilumab Basic information
Product Name:Abrilumab
Synonyms:Abrilumab;Research Grade Abrilumab(DHC98804);Research Grade Abrilumab;Abrilumab (anti-Integrin α4β7)
CAS:1342290-43-0
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Abrilumab Structure
Abrilumab Chemical Properties
form Liquid
color Colorless to light yellow
Safety Information
MSDS Information
Abrilumab Usage And Synthesis
UsesAbrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD)[1].
References[1] Iris Dotan, et al. The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-integrin therapies. Med Res Rev DOI:10.1002/med.21601
[2] Christopher A Lamb, et al. Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease. J Crohns Colitis. 2018 Aug 22;12(suppl_2):S653-S668. DOI:10.1093/ecco-jcc/jjy060
Abrilumab Preparation Products And Raw materials
Tag:Abrilumab(1342290-43-0) Related Product Information
Romosozumab Caplacizumab Emapalumab Denosumab Sirukumab Emibetuzumab Lenzilumab IMMunoglobulin G2 Immunoglobulin G 1 (human-mouse monoclonal BIWA4 gamma1-chain antihuman antigen CD44v8), disulfide with human-mouse monoclonal BIWA4 gamma-chain, dimer Motavizumab